Publications

Title Yearsort ascending
Amoxicillin/clavulanate in combination with rifampicin/clarithromycin is bactericidal against Mycobacterium ulcerans 2024
Evaluation of critical parameters in the hollow-fibre system for tuberculosis: A case study of moxifloxacin 2024
Susceptibility testing of the live attenuated tuberculosis vaccine BCG and the vaccine candidate MTBVAC to currently WHO-recommended anti-tuberculosis drugs by the European committee on antimicrobial susceptibility testing (EUCAST) method 2024
The novel drug candidate VOMG kills Mycobacterium abscessus and other pathogens by inhibiting cell division 2024
Repurposing β-Lactams for the Treatment of Mycobacterium kansasii Infections: An In Vitro Study 2023
Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium 2023
In vitro synergy screens of FDA-approved drugs reveal novel zidovudine- and azithromycin-based combinations with last-line antibiotics against Klebsiella pneumoniae 2023
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme 2022
Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial) 2022
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria 2021
Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency 2020
The FICI paradigm: correcting flaws in antimicrobial in vitro synergy screens at their inception. 2019
Sanfetrinem, repurposing an oral beta-lactam with intracellular activity for the treatment of tuberculosis 2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2019
Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening 2018
Targeting Tuberculosis: Existing drugs can – and should – be repurposed to fight neglected diseases. 2017
Targeting Tuberculosis: Existing drugs can - and should - be repurposed to fight neglected diseases. 2017
Repurposing clinically approved cephalosporins for tuberculosis therapy. 2016
Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains. 2013